Homburger advised Madrigal in connection with its new USD 500 m financing

On July 17, 2025, Madrigal Pharmaceuticals, Inc., a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need, secured a USD 500 m senior secured credit facility from Blue Owl Capital to advance its pharmaceutical pipeline. On September 4, 2025, Madrigal’s Swiss subsidiary, Madrigal Pharmaceuticals GmbH, acceded as guarantor and security provider to this financing.

Homburger advised Madrigal, in particular its Swiss subsidiary Madrigal Pharmaceuticals GmbH, with regard to all Swiss legal aspects of the financing transaction.

The Homburger team was led by Daniel Haeberli and included Fabrice Eckert, Luca Gmür and Yulia Shaburnykova (all Financing) as well as Stefan Oesterhelt (Tax).